• 1
    Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, et al.Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.Arthritis Rheum2013;65:214353.
  • 2
    Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al.A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.Arthritis Rheum2009;61:116878.
  • 3
    Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.Lancet2011;377:72131.
  • 4
    Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al.Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.Ann Rheum Dis2012;71:18338.
  • 5
    Feltkamp TE, Kirkwood TB, Maini RN, Aarden LA.The first international standard for antibodies to double stranded DNA.Ann Rheum Dis1988;47:7406.
  • 6
    Launay D, Schmidt J, Lepers S, Mirault T, Lambert M, Kyndt X, et al.Comparison of the Farr radioimmunoassay, 3 commercial enzyme immunoassays and Crithidia luciliae immunofluorescence test for diagnosis and activity assessment of systemic lupus erythematosus.Clin Chim Acta2010;411:95964.
  • 7
    Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, et al.Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.Arthritis Res Ther2008;10:R109.